Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $1.05, but opened at $1.20. Standard BioTools shares last traded at $1.42, with a volume of 8,634,191 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.
View Our Latest Stock Report on LAB
Standard BioTools Stock Up 1.6%
The firm's 50 day moving average is $1.10 and its two-hundred day moving average is $1.33. The stock has a market cap of $482.37 million, a price-to-earnings ratio of -3.63 and a beta of 1.50.
Institutional Trading of Standard BioTools
Hedge funds have recently made changes to their positions in the stock. Jump Financial LLC acquired a new position in shares of Standard BioTools during the first quarter valued at $26,000. Takeda Pharmaceutical Co. Ltd. acquired a new position in Standard BioTools during the 4th quarter valued at about $29,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Standard BioTools by 115.6% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock worth $29,000 after purchasing an additional 14,541 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Standard BioTools in the fourth quarter valued at approximately $30,000. Finally, CWM LLC raised its holdings in shares of Standard BioTools by 101.8% during the first quarter. CWM LLC now owns 29,705 shares of the company's stock valued at $32,000 after buying an additional 14,984 shares during the last quarter. Institutional investors own 53.74% of the company's stock.
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Stories
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
